An interventional study of Low-dose computed tomography of the chest in Lung Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · Assistance Publique - Hôpitaux de Paris.
Among the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 18th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →9 of the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50–74
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50–74 · Women only
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 50 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 235 across the 12 interventional studies, 100 across the 7 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
4 of the studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07739121Assistance Publique - Hôpitaux de ParisBenchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations | 2026-12-31 |
| NCT06244355Assistance Publique - Hôpitaux de ParisStudies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer | 2027-06 |
| NCT04300062Assistance Publique - Hôpitaux de ParisTumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer | 2027-08 |
| NCT05195385Assistance Publique - Hôpitaux de ParisLung Cancer Screening With Low-dose CT Scan in Women : Implementation Study | 2027-10-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective is to estimate the detection rate of lung cancer in the population screened by low-dose chest CT scans.
Low-dose CT screening (LDCT) allows for the detection of lung cancer at an early stage, enabling curative treatment. Large randomized controlled trials have demonstrated that LDCT reduces mortality in smokers.
The objective of the current research is not to confirm a reduction in mortality, but to show that screening can be safely implemented at a population level. Different modes of recruitment and invitation will be tested to ensure that LDCT can be implemented equitably. The role of artificial intelligence as an alternative to double human reading will also be assessed.
Screening strategy includes baseline, followed by 1-year LDCT, and a third LDCT 2 years later. Current smokers will be offered smoking cessation support.
The management of screen-detected lung nodules will follow the 2025 guidelines from the European Society of Thoracic imaging.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Temporary exclusion Criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baseline low-dose CT acquisition, then at 1 year and 3 years to depict suspicious lung nodules
Lung cancer detection rate in the population screened using low-dose chest CT
Number of individuals with detected cancer divided by the number of individuals included in the study, i.e., an intention-to-screen analysis.
Time frame: 42 months
Evaluation of screening performance
* True positives: positive screening result and confirmation of malignancy. * True negatives: negative screening result (absence of nodules, or nodules not meeting the criteria for a positive or indeterminate screening, see algorithms), including during retrospective review in cases where cancer is diagnosed within the following year. * False positives: positive screening result but malignancy not confirmed after appropriate investigation(s). * False negatives: CT screening considered negative, but cancer is diagnosed within the coming year and the CT scan is retrospectively interpreted as positive or indeterminate.
Time frame: 42 months
Exploration and comparison of several methods for identifying and inviting the target population
The identification and invitation of participants will be carried out using a multimodal approach: local and national press campaigns, outreach to insured individuals aged 50 to 74 in certain regions, and through an ambassador network (healthcare professionals, institutional representatives, associations, and citizens aware of lung cancer screening). Screening support tools will be deployed, including: * A website with a calculator to help determine eligibility; * A telephone call center to assess eligibility. Inclusions : Inclusions will be carried out by the participant's primary care physician if they are an investigator, or by other volunteer general practitioners, in health centers; by secondary care providers; or via outreach programs. The inclusion visits or teleconsultations will allow verifying the eligibility criteria and obtaining electronic consent.
Time frame: 18 months
Measurement of participation rate
The participation rate is defined as the number of individuals having performed at least one CT scan, divided by the number of eligible individuals.
Time frame: 18 months
Measurement of response rates to follow-up invitations
The investigators will measure the participation rate to follow-up invitations following an indeterminate CT scan result
Time frame: 42 months
Measurement of adherence to screening rounds
The investigators will measure the participation rate to screening at 1 year and 3 year
Time frame: 18 months , 30 months & 54 months
Measurement of the complication rate of invasive investigations in positive cases (true positives and false positives)
For participants with a positive screening result, the procedures, results, and complications of diagnostic actions (PET, endoscopy, CT-guided or ultrasound-guided biopsy, surgery) will be collected from the participants' medical records . The rate of early-stage lung cancers among the lung cancers diagnosed following a CT screening will also be measured (Evaluation criterion: number of lung cancers diagnosed at stage I or II divided by the total number of diagnosed lung cancers).
Time frame: 42 months
Measurement of the adherence rate to the offered smoking cessation support
The investigators will record the proportion of active smokers who either decline the systematically offered smoking-cessation assistance or fail to attend the scheduled appointment, as well as the factors underlying this refusal. The investigators will also assess smoking cessation rates during follow-up and identify their predictors.
Time frame: 48 months
Measurement of the adherence rate to smoking cessation support
The investigators will record the proportion of active smokers who declined smoking-cessation support or did not attend the scheduled appointments
Time frame: 48 months
Identification of reasons for refusal of smoking cessation support.
Investigators will collect the reasons selected by participants for refusing smoking cessation support from a pre-established list (e.g., concern about weight gain, fear of failure).
Time frame: 48 months
Measurement of smoking cessation rate
The investigators will assess smoking cessation rates during follow-up and identify their predictors.
Time frame: 48 months
Identification of the predictors of smoking cessation rates.
The investigators will identify the predictor of smoking cessation rates (correlation with age, gender, level of education, occupation, etc…)
Time frame: 48 months
Evaluation of the feasibility and relevance of a double reading of CT scans, and role of artificial intelligence
* Agreement in classifying cases as "screen-negative" versus "positive or indeterminate" between a single AI-assisted reading and a double AI-assisted reading (with a third adjudication in case of disagreement, serving as the reference), measured using the kappa coefficient. * Agreement in classifying cases as "screen-negative" versus "positive or indeterminate" between AI alone and the reference, measured using the kappa coefficient.
Time frame: 12 months
Measurement of the detection rate of coronary artery calcifications, pulmonary emphysema, osteoporosis, and incidental findings
For each of these anomalies, the detection rate will be calculated as the number of participants with the anomaly divided by the number of participants who underwent at least one CT scan. The presence and severity of emphysema (Fleischner classification), the Shemesh score, attenuation at the T8 level, and the diameter of the ascending aorta if \>4 cm will be systematically recorded in the structured CT screening report. Interstitial lung abnormalities (ILA, including Langerhans cell histiocytosis), osteoporotic compression fractures, and all anomalies requiring clinical care will also be systematically documented.
Time frame: 24 months
Impact of the program on healthcare pathways
The impacts on care pathways can be measured by evaluating the following time intervals, -Time between registration on the platform and completion of the inclusion visit, * Time between inclusion and completion of the initial CT scan, * Time until availability of radiology reports (single and double reading), * Time to first contact with a tobacco cessation specialist AND Using the date of the CT scan as the reference date: * Time to presentation of positive cases at the MDTB, * Time to a positive diagnosis (pathological report or MDTB report ) * Time to first treatment for positive cases requiring it, * Time to the first thoracic surgery consultation, * Time to surgery * Time to other consultations depending on incidental findings
Time frame: 42 months
Comparison of healthcare pathways
Healthcare utilization will be compared between screening-adherent and non-adherent patients, using two different denominators: the target population and the invited population after linkage with the SNDS (French National Health Data System).
Time frame: 42 months
Creation of a CT scan dataset
As part of the IMPULSION study, an imaging dataset for research and teaching purposes will be created, including all CT scans performed during the study (baseline, follow-up, and subsequent screening rounds), unless the participant explicitly objects.
Time frame: 42 months
Definition of a lung cancer risk score
Using the variables collected in the IMPULSION study, a predictive lung cancer risk score will be developed for the eligible population, specifically tailored to the French population.
Time frame: 42 months
Cost effectiveness analysis
The costs associated with screening (including surgical treatment of early-stage cancers and hospitalization for invasive procedures) will be compared with the costs that would have been incurred if the screen-detected lung cancers had all been diagnosed at an advanced stage.
Time frame: 42 months
Panel characteristics of participants
The objective of this sub-study is to conduct a qualitative analysis of the characteristics of participants in lung cancer screening and the program.
Time frame: 48 months
Panel - participant perceptions
Qualitative assessment of participant perceptions regarding lung cancer screening in a random sample of 2,000 participants enrolled in the main study.
Time frame: 48 months
Ultra low-dose
The objective is to assess whether this dose level, using modern techniques, provides information equivalent to that obtained with the dose used in the main protocol. A second ultra-low-dose acquisition (CTDI 0.15 mGy for weight \< 80 kg, CTDI 0.20 mGy for weight ≥ 80 kg) immediatly after the IMPULSION CT scan. The ultra-low-dose CT scan will be read exclusively in a centralized manner by a certified radiologist assisted by AI software, using the same criteria as those applied to the low-dose reference acquisition, and blinded to the low-dose CT data. An assessment of concordance will be performed in 2,500 participants.
Time frame: 1 day (baseline scanner)
Biobank
Collection of a maximum of 28 mL of whole blood (i.e., approximately 7 tubes of 5 mL with 4 mL collected per tube) for storage for research purposes. The collected samples are intended to create a biobank linked to clinical and radiological data. This biobank will make it possible to test various biomarkers for predicting individual cancer risk, the risk that a nodule is cancerous, or the risk of developing a disease evaluated in this cohort (including COPD, cardiovascular disease, osteoporosis, or interstitial lung disease).
Time frame: Inclusion (day 1)
Spirometry
The purpose of this examination is to assess lung volumes at inclusion visit. In participating an optional, spirometry will be performed at inclusion. The following mesaures will be recorded : FEV1 and FVC. Interpretation will be based on GOLD recommendations and using the GLI system for reference values. The following definitions will be used: * Pre-COPD: FEV₁ \< 80% and FEV₁/FVC ≥ 0.7 * Obstructive ventilatory defect (OVD): FEV₁/FVC \< 0.7 on spirometry * GOLD stages 1 to 4 according to the FEV₁ value. Participant questionnaire will also includes questions about chronic COPD symptoms in order to assess the presence of a COPD.
Time frame: Inclusion (day 1)
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for May 2031, 60 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 60 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →